Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401107 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL25940026 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL27998301 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL28674976 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL2332275 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL25830633 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL10666915 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL10347493 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL19711116 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS | |
| SCHEMBL10668987 | 1.00 | LMNA (0.52) | LMNADNM1PLA2G1BPLA2G2AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240117355-A1 | LIPOPROTEIN-MIMICKING SOLID LIPID NANOPARTICLES FOR DRUG DELIVERY AND USES THEREOF | TIONLAB THERAPEUTICS (KR) | 2024-04-11 | — | — | US | claimed |
| EP-4349328-A1 | LIPOPROTEIN-MIMICKING SOLID LIPID NANOPARTICLES FOR DRUG DELIVERY AND USES THEREOF | Tionlab Therapeutics (KR) | 2024-04-10 | — | — | EP | claimed |
| EP-3357491-B1 | PHARMACEUTICAL COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2021-06-02 | — | — | EP | claimed |
| US-20210077406-A1 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2021-03-18 | — | — | US | claimed |
| US-20210052623-A1 | LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION OF DNA FRAGMENT MIXTURE AND HAVING FLUIDITY AND PREPARATION METHOD THEREFOR | PHARMARESEARCH PRODUCTS CO., LTD. (KR) | 2021-02-25 | — | — | US | claimed |
| EP-3763357-A1 | LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION OF DNA FRAGMENT MIXTURE AND HAVING FLUIDITY AND PREPARATION METHOD THEREFOR | Pharmaresearch Products Co., Ltd. (KR) | 2021-01-13 | — | — | EP | claimed |
| EP-2833869-B1 | METHOD OF PREPARING COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2020-10-28 | — | — | EP | claimed |
| WO-2019098691-A9 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | 주식회사 삼양바이오팜 | 2019-08-29 | — | — | WO | claimed |
| US-10292932-B2 | Polymeric micelle particle comprising anionic drugs and method of preparing the same | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2019-05-21 | — | — | US | claimed |
| US-20180250409-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2018-09-06 | — | — | US | claimed |
| EP-1198256-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME CORPORATION (US) | 2002-04-24 | — | — | EP | claimed |
| US-6339069-B1 | ADMINISTERING FORMULATION COMPRISING PHARMACEUTICALLY ACCEPTABLE CARRIER; AND, LIPOSOME COMPRISING A BIOACTIVE AGENT AND A LIPID COMPONENT, THE LIPID COMPONENT COMPRISING A PEPTIDE-LIPID CONJUGATE | ELAN PHARMACEUTICALSTECHNOLOGIES, INC. | 2002-01-15 | — | — | US | claimed |
| WO-2001000247-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 2001-01-04 | — | — | WO | claimed |
| US-6143716-A | CONTROLLED DELIVERY SYSTEM TO DELIVER LIPOSOMAL DRUGS IN VITRO OR IN VIVO, FOR EXAMPLE, IN TREATMENT OF MAMMALS AFFLICTED WITH VARIOUS DISEASES, DISORDERS OR CONDITIONS, E.G., CANCERS | THE LIPOSOME COMPANY, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| WO-2000000033-A1 | MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-06 | — | — | WO | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| EP-0758883-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME CORPORATION (US) | 1997-02-26 | — | — | EP | claimed |
| US-5552155-A | Fusogenic lipsomes and methods for making and using same | THE LIPOSOME COMPANY, INC. (US) | 1996-09-03 | — | — | US | claimed |
| WO-1995027478-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME COMPANY, INC. (US) | 1995-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077406-A1 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | ANXA6, PHOSPHO1, ABHD16A | LMNA 3154/4885DNM1 706/4885PLA2G1B 297/4885 |
| US-20180250409-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR | THEM6, NOTUM, CETP | LMNA 1750/4885DNM1 847/4885PLA2G1B 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.